BioMarin Pharmaceutical Inc. (BMRN) TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM EST
Company Participants
Alexander Hardy – President, CEO & Director
Brian Mueller – CFO & Executive VP
Conference Call Participants
Philip Nadeau – TD Cowen, Research Division
Presentation
Philip Nadeau
TD Cowen, Research Division
Good morning, and welcome once again to TD Cowen’s 46th Annual Healthcare Conference. I’m Phil Nadeau, one of the biotech analysts here at Cowen, and it’s my pleasure to do a fireside chat with BioMarin Pharmaceutical. We have with us today, Alexander Hardy, the President and CEO; and Brian Mueller, the Executive Vice President and CFO. Guys, maybe I’ll kick it to you to begin. Could you give a brief state of the company overview, biggest strengths, biggest challenges? And what does BioMarin need to achieve to outperform over the next year or 2?
Question-and-Answer Session
Alexander Hardy
President, CEO & Director
Excellent. Well, thanks very much. Thanks, everybody, for joining us. So I’ve been CEO of BioMarin for the last 2 years and started off with a kind of a strategic refresh, what’s the strategy of the company. It was very clear to me that BD should play a significant role in the future of BioMarin, hadn’t played much of a role beyond early BD up to that point because we’ve got some really clear competitive advantages of being a rare disease company operating at scale. So it’s really cool to have done 2 M&A last year, buying Inozyme and then obviously, the acquisition of Amicus, which is on track to close in the second quarter of this year.
So we’ve got that together with the enzyme therapy business is going to drop right into those — both of those acquisitions will drop right into our enzyme therapy business, which is already
